Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported-281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months-65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation

Berchialla, Paola;Dogliotti, Irene;Cerrano, Marco;Ferrero, Dario;Giai, Valentina;Saglio, Giuseppe;Fava, Carmen
2020

Abstract

Successful discontinuation of tyrosine kinase inhibitors has been achieved in patients with chronic-phase chronic myeloid leukemia (CML). Careful molecular monitoring after discontinuation warrants safe and prompt resumption of therapy. We retrospectively evaluated how molecular monitoring has been conducted in Italy in a cohort of patients who discontinued tyrosine kinase inhibitor (TKI) treatment per clinical practice. The outcome of these patients has recently been reported-281 chronic-phase CML patients were included in this subanalysis. Median follow-up since discontinuation was 2 years. Overall, 2203 analyses were performed, 17.9% in the first three months and 38.4% in the first six months. Eighty-six patients lost major molecular response (MMR) in a mean time of 5.7 months-65 pts (75.6%) during the first six months. We evaluated the number of patients who would experience a delay in diagnosis of MMR loss if a three-month monitoring schedule was adopted. In the first 6 months, 19 pts (29.2%) would have a one-month delay, 26 (40%) a 2-month delay. Very few patients would experience a delay in the following months. A less intense frequency of monitoring, particularly after the first 6 months off treatment, would not have affected the success of treatment-free remission (TFR) nor put patients at risk of progression.
9
11
3692
3701
chronic myeloid leukemia; molecular monitoring; treatment-free remission
Dragani, Matteo; Rege Cambrin, Giovanna; Berchialla, Paola; Dogliotti, Irene; Rosti, Gianantonio; Castagnetti, Fausto; Capodanno, Isabella; Martino, Bruno; Cerrano, Marco; Ferrero, Dario; Gambacorti-Passerini, Carlo; Crugnola, Monica; Elena, Chiara; Breccia, Massimo; Iurlo, Alessandra; Cattaneo, Daniele; Galimberti, Sara; Gozzini, Antonella; Bocchia, Monica; Lunghi, Francesca; Cedrone, Michele; Sgherza, Nicola; Luciano, Luigia; Russo, Sabina; Santoro, Marco; Giai, Valentina; Caocci, Giovanni; Levato, Luciano; Abruzzese, Elisabetta; Sora, Federica; Saglio, Giuseppe; Fava, Carmen
File in questo prodotto:
File Dimensione Formato  
Dragani et al_jcm-2020.pdf

Accesso aperto

Tipo di file: PDF EDITORIALE
Dimensione 603.94 kB
Formato Adobe PDF
603.94 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1786553
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 3
social impact